Blueprint Medicines Soars 27% on $9.5 Billion Buyout. Why This Drug Is Key to the Deal.

Sanofi to Acquire Blueprint Medicines for Up to $9.5 Billion

Blueprint Medicines price target lowered by $11 at Wedbush, here's why

Blood Cancer-Focused Blueprint Medicines Could Be 'Attractive Target For Partnerships': Analyst